J Herrstedt, R Clark-Snow, C H Ruhlmann, A Molassiotis, I Olver, B L Rapoport, M Aapro, K Dennis, P J Hesketh, R M Navari, L Schwartzberg, M L Affronti, M A Garcia-Del-Barrio, A Chan, L Celio, R Chow, M Fleury, R J Gralla, R Giusti, F Jahn, H Iihara, E Maranzano, V Radhakrishnan, M Saito, P Sayegh, S Bosnjak, L Zhang, J Lee, V Ostwal, T Smit, A Zilic, K Jordan, F Scotté
• Nausea and vomiting are considered amongst the most troublesome adverse events for patients receiving antineoplastics. • The guideline covers emetic risk classification, prevention and management of treatment-induced nausea and vomiting. • The Consensus Committee consisted of 34 multidisciplinary, health care professionals and three patient advocates. • Recommendations are based on evidence-based data (level of evidence) and the authors’ collective expert opinion (grade)...
February 2024: ESMO Open